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INTRODUCTION
Endometriosis is an endometrium-like lesion out-
side of the uterine cavity that is sensitive to the
hormonal changes in the menstrual cycle.1,2 The
prevalence of endometriosis in women of repro-
ductive age is around 10%.3,4 This condition is
more frequently encountered in women with pel-
vic pain and infertility, in which 35-50% have en-
dometriosis.2 Data from RS Dr. Cipto Mangunku-
sumo in 2000-2005 showed 111 new cases of en-
dometriosis diagnoses by laparoscopy, 75% of
which are found in women aged 25-39 years.5,6
Currently, most cases of endometriosis are
treated with hormones, that may influence the
menstrual cycle and fertility of the patients.1,7 Non-
hormonal treatments such as NSAID (non-steroidal
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Abstrak
Tujuan: Menilai keberadaan reseptor PPARy serta membandingkanekspresi reseptor PPARy pada endometrium eutopik dan ektopik pada
penderita endometriosis.
Metode:  Penelitian ini merupakan penelitian potong lintang (cross
sectional). Sepuluh subjek penderita endometriosis yang menjalani la-
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yakni endometrium eutopik dan endometrium ektopik yang berasaldari dinding kista endometriosis saat dilakukan pembedahan, kemu-
dian dilihat ekspresi reseptor PPARy dengan two-step RT-qPCR. Eks-
presi masing-masing sampel diuji statistik dengan uji t berpasangandan tes korelasi Pearson.
Hasil:  Didapatkan ekspresi reseptor PPARy pada endometrium eu-topik dan ektopik penderita endometriosis dengan metode RT-qPCR.
Ekspresi reseptor PPARy endometrium eutopik dan ektopik didapat-kan secara statistik tidak berbeda bermakna (1.16 lipatan relatif vs
1.25 lipatan relatif; p=0.26). Pada uji korelasi Pearson didapatkakan
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anti-inflammatory drugs) do not interfere with fer-
tility, but long-time treatment with such agents
may pose significant side effects.1,2,7 A non-hormo-
nal treatment that can be used for a long period
without significant side effects and with no impact
on fertility is urgently needed for endometriosis
patients who wish to conceive. Understanding the
pathogenesis of endometriosis may open doors to
other treatment modalities, either by methods that
are already available or under development.1,3,7-9
One agent that may be used as a modulator is
the activation of PPARy receptor, which is widely
recognized in the treatment of diabetes.3,10 The po-
tential role of PPARy in the pathogenesis of en-
dometriosis and as an alternative non-hormonal
treatment encouraged us to study the profile of
PPARy receptors in patients with endometriosis.
Researchers have widely known that activation
of PPARy influences the differentiation of adipo-
cytes and insulin resistance.11 PPARy may also in-
fluence the production of proinflammatory cytoki-
nes by systemic immune cells and cells in perito-
neal fluids, acting as an external factor to the
development of endometrial tissue in the perito-
neum.12-16 Development in the last decade showed
that PPARy may effect the profile of certain genes
in eutopic and ectopic endometrium.17,18 These
facts encouraged us to conduct a research, to find
differences between the profile of PPARy genes in
eutopic and ectopic endometrium and to elaborate
the role of PPARy in the development of local en-
dometriosis tissue.
Significant gene profile differences have been
identified in eutopic and ectopic endometriosis tis-
sue.19-21 Several studies have revealed higher aro-
matase profiles in the nucleus of ectopic glandu-
lar endometrium compared to eutopic endometri-
um.22-24 Factors enhancing neovascularisation,
VEGF, and adhesion factors, CAM, are also more
abundant in ectopic endometrium.25,26 The profile
of apoptosis-regulator genes, Bcl-2 and Bax, are
also different in eutopic and ectopic endome-
trium.27
Administration of PPARy ligands may inhibit ad-
hesion of endometrial cells to the peritoneum by
reducing the expression of ICAM-12.28,29 The influ-
ence of PPARy on implants and neovascularization
is proven by reduced VEGF activity, thus inhibiting
neovascularization.19 Activation of PPARy also re-
duces aromatase, thus reducing the production of
estrogen in endometriosis lesions and reducing the
proliferation of endometriosis lesions in vitro.30
One study also reported reduction of anti-apoptotic
genes in endometriosis lesions which had PPARy
ligands administered.31
Administration of PPARy ligand agonists in ani-
mal with endometriosis also reduced the size and
mass of ectopic endometrium.32 In baboons, it re-
duced the size and area of pelvic endometriosis.33
In humans, administration of PPARy agonists re-
duced pain symptoms.35 It has been reported that
increased PPARy expression (determined through
immunohistochemistry) in peritoneal lesions re-
duced symtomps in endometriosis patients, espe-
cially pelvic pain, dysmenorrhea, and dyspareu-
nia.34,35
The role of PPARy is determined by both the
availability of ligands and expression of its recep-
tor.32-35 Expression of PPARy receptor in endo-
metriosis tissue may be useful to study its role in
the pathogenesis of endometriosis and as a predic-
tor in determining the response to therapy with
PPARy ligands.34,35 We conducted this study to
evaluate the expression of the PPARy and to com-
pare its expression in eutopic and ectopic endo-
metrium in reproductive age women with endo-
metriosis.
METHODS
This a biomedical science study with cross sec-
tional design, and with numerical comparison
between two-paired group analysis. We collected
data from February to April 2014. Subjects were
recruited from general gynecology patients and pa-
tients from the fertility clinic who underwent sur-
gery in the Department of Obstetrics and Gyneco-
logy, RS Cipto Mangunkusumo, Jakarta. Samples
were analyzed in the Integrated Laboratory, Fa-
culty of Medicine University of Indonesia.
Samples were obtained using endometrial bi-
opsy when subjects were in the operating room.
Samples were transported, then total DNA extrac-
tion was performed. After that, samples were
stored in -80°C until analysis was performed. After
all samples were collected, frozen endometrial tis-
sues were thawed, and RT-PCR was conducted to
assess the expression of PPARy receptors in the
endometrium.
RT-PCR examination of PPARy receptors was in-
itiated by thawing of samples stored in RNA ladder
in room temperature, followed by RNA isolation.
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The result of RNA isolation was total RNA of sam-
ples in elution buffer solution.
Development of cDNA from total RNA was
started by assessment of concentration and purity
of RNA by using spectrum analyzer in 260 nm and
280 nm wavelength. To assess the expression of
PPARy with qPCR, we designed primers in silico
(with computers) with IDT (Integrated DNA tech-
nologies) software, and we obtained the sequence
of target and reference genes.
All qPCR were performed with Rotor Gene Q®
machine. Quantification for each sample was calcu-
lated by using the CT (Cycle threshold) from target
genes (PPARy) and the CT from reference genes
(GAPDH). Semiquantification of gene expression
was carried out with Livak method.37
RESULTS
We identified 49 patients who underwent surgery
for endometriosis cysts from February to April
2014. Eighteen patients were excluded: 12 did not
sign the consent form, 2 patients had tubo-ovarial
abcess, 2 patients had obesity, and 2 patients were
smokers. From the remaining 31 patients, we did
not obtain adequate endometrial samples (nil or
less than 0.5 ml). Seventeen patients were ade-
quate for analysis, however to due to limited funds
for reagens and material, only 10 patients (20 sam-
ples) were analyzed. The remaining 7 pair of sam-
ples were stored in -80°C for further studies.
This study included 10 subjects. All subjects un-
derwent surgery for endometriosis cysts. The
mean age of patients was 31.8±4.15 years, with
BMI 22.21±1.38 kg/m2, waist-hip ratio 0.81±0.52
cm, and mean leukocyte count 8,033±1,897. All
subjects were stage III-IV endometriosis patients
with endometriosis cysts; the mean size of the
cysts was 6.8±2,1 cm and all subjects experienced
menstrual pain with a mean visual analogue scale
(VAS) 6.3±1.15. It could be concluded that the sub-
jects belonged to a homogenoud group, which is
women of reproductive age with menstrual pain
and endometriosis cysts, with normal BMI and
without other comorbidities.
Surgery (Laparoscopy/Laparotomy)
Patients from REI Clinic
Suspected
endometriosis
INCLUSION EXCLUSION
ENDOMETRIOSIS
ENDOMETRIOSIS CYST
TISSUE & ENDOMETRIAL
BIOPSY
Assessment of PPARy
expression
Expression of PPARy receptor
ENDOMETRIOSIS CYST TISSUE VS EUROIKB
Figure 1. Research workflow.
Figure 2. Normality plots of CT (Cycle Threshold) qPCR PPARy in Eutopic (left) and Ectopic Endometrium (right)
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Quanitification of receptor expression was per-
formed with Livak method by using the following
formula: 2-ΔΔ CT [ΔΔCT= ΔCT - (median CT PPARy -
median CT GAPDH)].37 The result of this formula is
a relative time-fold towards the reference gene
(GAPDH), a housekeeping gene whose expression
is constant in all tissues.
The mean expression of PPARy in eutopic and
ectopic endometrial tissue was 1.16u and 1.25u,
respectively. Normality tests towards the CT (Cycle
threshold) data using Kolmogorov-Smirnov and
Shapiro-Wilks revealed normal distribution in both
groups (p>0.05).
As the data was normally distributed and ob-
tained from the same patient (eutopic and ectopic
tissue), we conducted a paired t-test to find the dif-
ference between both groups. We found that the
expression of PPARy in ectopic endometrium was
higher than in eutopic endometrium, but the dif-
ference was not significantly different (1.25 vs.
1.16, p=0.26) (Table 1).
Table 1. Comparison of PPARy Receptor Expression
Mean PPARy receptor expression
(Unit= relative­folds to GADPH, a reference gene) p
Difference
of mean
Eutopic
tissue 1.16 0.26 0.09
Ectopic
tissue 1.25
On Pearson correlation test we found a weak
correlation between the expression of PPARy re-
ceptor in ectopic endometrium and eutopic en-
dometrium (r = 0.16), as shown Table 2.
Table 2. Correlation between PPARy Expression in Ec-
topic and Eutopic Endometrium in Endometriosis Patients
Mean r
PPARy receptor expression in
eutopic endometrium 1.16 0.16
PPARy receptor expression in
ectopic endometrium 1.25
 
DISCUSSION
MacLaren et al found that PPARy can be found in
the reproductive system of mice and bovine.37
Pritts et al reported that PPARy was ultimately ex-
pressed in the nucleus of cultured endometrial tis-
sue.17 Peeters et al assessed the expression of
PPARy in cultured endometrial cells using immu-
nohistochemistry and RT-PCR, and its effect on ad-
ministration of PPARy agonists and expression of
VEGF.18 Until now, no study have assessed the ex-
pression of PPARy in ectopic and eutopic endo-
metrial tissue in women with endometriosis and
identifying the correlation between both groups.
In this study we obtained the expression of
PPARy receptor in eutopic and ectopic endome-
trium in patients with endometriosis, which indi-
cates that the PPARy ligand may directly influence
endometrial tissue or locally, and may be the back-
ground for the administration of PPARy agonists in
patients with endometriosis. Ohama et al found
that administration of PPARy agonistsmay lower
TNFy and IL-8 in endometrial tissue.38 Lebovic et
al proved that PPARy agonists significantly reduce
the size of endometriosis lesions in mice and pri-
mates.32,33 One of the possible mechanism for their
findings are through the role of PPARy receptors
in target tissue (eutopic and ectopic endometrium),
as we have found in this study.
This study also revealed that the expression of
PPARy receptors in eutopic and ectopic endo-
metrium was not significantly different (p>0.05),
which shows a correlation between the profile of
eutopic and ectopic endometrial tissue. This is in
line with other studies stating that endometriosis
is a disease of eutopic endometrium.19,20 Afshar et
al found that gene expression abnormalities in
eutopic endometrium may influence the behaviour
of ectopic endometrium in primates.19 Further-
more, Sha et al discovered that gene expression ab-
normalities identified by qPCR in eutopic endo-
metrium of endometriosis patients compared to
endometrium in patients without endometriosis
may lead to the survival of endometrium under-
going retrograde menstruation.20 Wren et al also
concluded from 562 genes analyzed with micro-
array from several studies, that there are multiple
correlations between expression of those genes in
eutopic and ectopic endometrium.21 Beside our
study, until now there has been no study assessing
the expression of PPARy receptors in eutopic and
ectopic endometrium.
We found a positive weak correlation between
expression of PPARy receptor in eutopic and ec-
topic endometrium of endometriosis patients
(r=0.16). This shows that only 16% of PPARy re-
ceptor expression in eutopic or ectopic endome-
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trium can be predicted from the PPARy receptor
expression in their counterparts in patients with
endometriosis. This means that the expression of
PPARy in eutopic endometrium samples did not
entirely represent its expression in ectopic en-
dometrium samples, and vice versa. A further
study on PPARy receptor expression in endome-
trial samples from subjects without endometrio-
sis is needed to evaluate the correlation between
PPARy receptor expression in eutopic and ectopic
endometrium of endometriosis patients and pa-
tients without endometriosis.
CONCLUSION
Expression of PPARy receptor in eutopic and ec-
topic endometrial tissue was not significantly dif-
ferent. Therefore, we can conclude that eutopic and
ectopic endometrial tissue in endometriosis pa-
tients have several similarities. This also means
that PPARy receptor may have a role in the patho-
physiology of endometriosis in eutopic endome-
trium of endometriosis patients.
Our results also demonstrates the potential role
of PPARy in the pathophysiology and pathogenesis
of local endometriosis in endometriosis lesions and
eutopic endometrium of endometriosis patients.
Knowledge on pathophysiology of endometriosis is
essential to understand the pathogenesis, diagno-
sis, and treatment of endometriosis. Each study
trying to solve the puzzle of endometriosis may
further the progress towards the understanding of
endometriosis.
This study could be continued with samples
from patients without endometriosis as the control
group, if it is ethically approved. Further studies
using samples from various endometriosis samples
such as superficial lesions, deeply infiltrating en-
dometriosis, and from endometriosis patients with
various stages of endometriosis could also provide
significant data on cracking the puzzle of endo-
metriosis.
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